TNB-486 is under clinical development by AstraZeneca and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect TNB-486’s likelihood of approval (LoA) and phase transition for B-Cell Non-Hodgkin Lymphoma took place on 22 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 22 Aug 2022 increased TNB-486’s LoA and decreased Phase Transition Success Rate (PTSR) for Diffuse Large B-Cell Lymphoma, increased LoA and decreased PTSR for Follicular Lymphoma, and increased LoA and decreased PTSR for Marginal Zone B-cell Lymphoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TNB-486 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
TNB-486 is under development for the treatment of B-cell leukemia and B-cell non-Hodgkin’s lymphomas including high grade B cell lymphoma, B-cell Non Hodgkin lymphoma, marginal zone lymphoma (MZL), diffuse large B cell lymphoma, high-grade B-cell lymphoma, follicular lymphoma. The therapeutic candidates are bi-specific human heavy chain antibodies. They act by targeting immune checkpoint inhibitors. The drug candidates are developed based on high-affinity UniDab molecules from uniRat technology. UniRat is a transgenic rat that uses human immunoglobulin heavy-chain translocus to express a diverse repertoire of human heavy chain antibodies.
It was also under development for the treatment of mantle cell lymphoma.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
Quick View TNB-486 LOA Data
|Highest Development Stage|